Phase II trial of trimetrexate in patients with advanced renal cell carcinoma

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

“…Preclinical trials with massive doses in beagle dogs demonstrated mild, reversible hepatotoxicity and diarrhea as the only adverse effects [4]. Several phase II trials have already been conducted in head and neck cancer [6], renal cell cancer [7], and colon cancer [8]. The daily x 5 every 28 day schedule selected for this trial found the maximum tolerated dose to be 800 mg/m 2 with reversible hepatotoxicity being dose-limiting and no evidence of myelosuppression [5].…”

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

“…Preclinical trials with massive doses in beagle dogs demonstrated mild, reversible hepatotoxicity and diarrhea as the only adverse effects [4]. Several phase II trials have already been conducted in head and neck cancer [6], renal cell cancer [7], and colon cancer [8]. The daily x 5 every 28 day schedule selected for this trial found the maximum tolerated dose to be 800 mg/m 2 with reversible hepatotoxicity being dose-limiting and no evidence of myelosuppression [5].…”

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

“…Preclinical trials with massive doses in beagle dogs demonstrated mild, reversible hepatotoxicity and diarrhea as the only adverse effects [4]. Several phase II trials have already been conducted in head and neck cancer [6], renal cell cancer [7], and colon cancer [8]. The daily x 5 every 28 day schedule selected for this trial found the maximum tolerated dose to be 800 mg/m 2 with reversible hepatotoxicity being dose-limiting and no evidence of myelosuppression [5].…”

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

“…Preclinical trials with massive doses in beagle dogs demonstrated mild, reversible hepatotoxicity and diarrhea as the only adverse effects [4]. Several phase II trials have already been conducted in head and neck cancer [6], renal cell cancer [7], and colon cancer [8]. The daily x 5 every 28 day schedule selected for this trial found the maximum tolerated dose to be 800 mg/m 2 with reversible hepatotoxicity being dose-limiting and no evidence of myelosuppression [5].…”